Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracoronary low-dose recombinant streptokinase during primary PCI for STEMI (caIMR-focused trial)
ChiCTR2600126944Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of streptokinase in acute ST-segment elevation myocardial infarction (STEMI) (2 arms), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Post-procedure immediate angiography-based index of microcirculatory resistance (caIMR). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
streptokinase
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on ChiCTR2600126944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126944.